Progress of PD-1/PD-L1 immune checkpoint inhibitors in the …
6 days ago · In particular, in the treatment of TNBC with PD-1/PD-L1 inhibitors, both monotherapy and combination chemotherapy, as well as targeted drugs and other therapeutic strategies, …
PD-L1-Positive High-Grade Triple-Negative Breast Cancer …
We analyzed the prognostic and predictive significance of PD-L1 (SP142 assay) immunohistochemical expression on TNBC patients’ samples as illustrated by pCR with regard …
Determining PD-L1 Status in Patients With Triple-Negative Breast …
Jul 20, 2021 · Triple-negative breast cancer (TNBC) accounts for approximately 12% to 17% of all breast cancers and has an aggressive clinical behavior. Increased tumor-infiltrating …
Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast ...
The combination of PD-1/PD-L1 inhibitors and chemotherapy could improve the survival and prognosis of patients with early and advanced TNBC. Combination treatment may be harmful …
PD-L1 Expression in Triple Negative Breast Cancer - PMC
This study was undertaken to determine whether PD-L1 is overexpressed in triple-negative breast cancer (TNBC) and to investigate the loss of the phosphatase and tensin homolog (PTEN) as …
Progress of PD-1/PD-L1 immune checkpoint inhibitors in the
6 days ago · In particular, in the treatment of TNBC with PD-1/PD-L1 inhibitors, both monotherapy and combination chemotherapy, as well as targeted drugs and other therapeutic strategies, …
PD-1 Independent Role of PD-L1 in Triple-Negative Breast …
Mar 29, 2023 · This study shows the intrinsic role of PD-L1 in TNBC independently of its binding to PD-1 receptors on T cells. It may pave the way for developing novel therapeutic strategies …
PD-1/PD-L1 immune checkpoint inhibitors in the treatment of ...
Oct 31, 2024 · Both PD-1 and PD-L1 inhibitors can offer survival benefits to TNBC patients, with the primary beneficiaries being those who are PD-L1-positive. However, immunotherapy can …
Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple …
In addition to the presence of TILs, the expression of immune evasion molecules in the tumor microenvironment, such as programmed death ligand 1 (PD-L1), can affect the prognosis of …
Immune modulation in solid tumors: a phase 1b study of …
Mar 18, 2025 · BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. Cancer Lett. 2019;465:45–58. Article …
- Some results have been removed